Digital Health Leader Mark Hirschhorn Joins Hygieia Board as Company Ramps Up for Growth of Its Unique d-Nav® Insulin Manage...
March 01 2021 - 07:23AM
Business Wire
Demand grows for d-Nav, the first FDA-cleared
technology to automatically adjust a medication dose
Hygieia, a digital health company, is accelerating its
operations as demand increases for d-Nav®, the only FDA-cleared
technology that automates dose adjustments for patients who inject
insulin. To help guide its aggressive growth initiatives, Hygieia
has added Mark Hirschhorn, Talkspace president, COO and CFO, to its
board of directors.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20210301005090/en/
Mark Hirschhorn, President, COO & CFO
at Talkspace, is joining the board of directors at Hygieia, makers
of the d-Nav insulin management app. (Photo: Business Wire)
Hirschhorn will tap into his experience with telehealth giants
Teladoc Health and Talkspace to advise Hygieia on its expansion
strategy. At Teladoc, Hirschhorn was responsible for the company’s
growth strategy, including the acquisition of BetterHelp, which he
managed as the company grew into one of the largest online
marketplaces for direct-to-consumer behavioral health. Under
Hirschhorn’s leadership, Teladoc grew from $10M in revenue with 45
employees to $500M and 2,500 employees.
“Mark joins our board during a time of unprecedented company
growth and in a market that is uniquely primed for innovation,”
said Eran Bashan, Hygieia CEO and Co-Founder. “Mark has the perfect
combination of expertise in the digital health industry and will
help us navigate this transitional period.”
Hygieia is answering the increased demand for its unique d-Nav
insulin management app. d-Nav uses AI-powered technology to
automate an insulin dose adjustment. It is the first FDA-cleared
technology to adjust a medication dose directly to the patient,
acting as a surrogate for a physician giving users real-time
recommendations.
The result is safe and effective insulin treatment that has
nearly 90 percent of patients seeing improved A1c levels within 90
days.
“Today’s health care environment desperately needs medical
technology solutions like d-Nav, which automate tasks and operate
remotely,” says Hirschhorn. "I'm excited to join Hygieia’s board as
the company begins to experience significant growth, and I'm
looking forward to helping them drive better care for people with
type 2 diabetes."
“We believe the standard of insulin therapy needs to change so
that every person injecting insulin gets frequent and regular
titration. Only d-Nav can automate insulin dose adjustments at the
user level. This is why we are readying for explosive growth,” said
Bashan.
Also, Hygieia has augmented its advisory board with the addition
of nationally recognized physician experts:
- Health insurance benefit design expert A. Mark Fendrick,
M.D., is helping Hygieia shape its payment model to enable
increased patient access to d-Nav.
- World-renowned endocrinologist George Grunberger, M.D.,
is advising Hygieia on physician and clinical outreach.
For more information on Hygieia and the d-Nav insulin management
technology, visit hygieia.com or call 734-369-9980.
About Hygieia/ d-Nav Insulin Management Program
Hygieia is a specialty provider of insulin therapy and maker of
the d-Nav® Insulin Management Program. The d-Nav program includes
an AI-powered application that helps people with type 2 diabetes
use insulin in a safe and effective way to control their blood
sugar levels. Studies show that some 90 percent of people using
d-Nav achieve lower A1C within three months. The d-Nav Insulin
Management Program was developed by two University of Michigan
researchers and has been peer-reviewed with studies published in
leading medical journals. Hygieia is headquartered in Livonia,
Michigan. Learn more at hygieia.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210301005090/en/
Debbie Reinheimer, debbie@reinheimerpr.com, 248-227-3667